Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 148 articles: HTML format

Single Articles

April 2024
1. NAM A, Jain S, Wu C, Campos A, et al
   Integrin alphavbeta3 Upregulation in Response to Nutrient Stress Promotes Lung Cancer Cell Metabolic Plasticity.
   Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/0008-5472.CAN-23-2700.
   PubMed     Abstract available
   
   
   
2. LIU Y, Murazzi I, Fuller AM, Pan H, et al
   Sarcoma Cells Secrete Hypoxia-Modified Collagen VI to Weaken the Lung Endothelial Barrier and Promote Metastasis.
   Cancer Res. 2024;84:977-993.
   PubMed     Abstract available
   
   
   
3. XU Y, Deng C, Chen H, Song Y, et al
   Osteosarcoma Cells Secrete CXCL14 That Activates Integrin alpha11beta1 on Fibroblasts to Form a Lung Metastatic Niche.
   Cancer Res. 2024;84:994-1012.
   PubMed     Abstract available
   
   
   March 2024
4. GAI X, Liu Y, Lan X, Chen L, et al
   Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer.
   Cancer Res. 2024 Mar 19. doi: 10.1158/0008-5472.CAN-23-2095.
   PubMed     Abstract available
   
   
   
5. WANG H, Zhang Y, Tian Y, Yang W, et al
   DNA-PK-Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance.
   Cancer Res. 2024;84:688-702.
   PubMed     Abstract available
   
   
   February 2024
6. HU B, Wiesehofer M, de Miguel FJ, Liu Z, et al
   ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
   Cancer Res. 2024 Feb 15. doi: 10.1158/0008-5472.CAN-23-0438.
   PubMed     Abstract available
   
   
   
7. ALEWINE C
   Macrophages Under the Influence of Tumor Mesothelin Weaken Host Defenses against Pancreatic Cancer Metastasis.
   Cancer Res. 2024;84:513-514.
   PubMed     Abstract available
   
   
   
8. RIGAMONTI A, Viatore M, Polidori R, Rahal D, et al
   Integrating AI-powered digital pathology and imaging mass cytometry identifies key classifiers of tumor cells, stroma, and immune cells in non-small cell lung cancer.
   Cancer Res. 2024 Feb 5. doi: 10.1158/0008-5472.CAN-23-1698.
   PubMed     Abstract available
   
   
   January 2024
9. MU M, Huang CX, Qu C, Li PL, et al
   Targeting ferroptosis-elicited inflammation suppresses hepatocellular carcinoma metastasis and enhances sorafenib efficacy.
   Cancer Res. 2024 Jan 17. doi: 10.1158/0008-5472.CAN-23-1796.
   PubMed     Abstract available
   
   
   
10. SAGGESE P, Pandey A, Alcaraz M Jr, Fung E, et al
    Glucose Deprivation Promotes Pseudohypoxia and Dedifferentiation in Lung Adenocarcinoma.
    Cancer Res. 2024;84:305-327.
    PubMed     Abstract available
    
    
    December 2023
11. NIU X, Martinez L
    Harnessing p53 to Improve Immunotherapy for Lung Cancer Treatment.
    Cancer Res. 2023 Dec 21:OF1-OF2. doi: 10.1158/0008-5472.CAN-23-3929.
    PubMed     Abstract available
    
    
    
12. DU M, Xin J, Zheng R, Yuan Q, et al
    CYP2A6 activity and cigarette consumption interact in smoking-related lung cancer susceptibility.
    Cancer Res. 2023 Dec 20. doi: 10.1158/0008-5472.CAN-23-0900.
    PubMed     Abstract available
    
    
    
13. MUKHOPADHYAY S, Huang HY, Lin Z, Ranieri M, et al
    Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.
    Cancer Res. 2023;83:4095-4111.
    PubMed     Abstract available
    
    
    
14. NIU X, Martinez L
    Harnessing p53 to improve immunotherapy for lung cancer treatment.
    Cancer Res. 2023 Dec 14. doi: 10.1158/0008-5472.CAN-23-3929.
    PubMed     Abstract available
    
    
    
15. XIA L, Liu JY, Yang MY, Zhang XH, et al
    Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells.
    Cancer Res. 2023 Dec 14. doi: 10.1158/0008-5472.CAN-23-1632.
    PubMed     Abstract available
    
    
    
16. MICHAUD DE, Guerriero JL
    Myeloid cells pave the metastatic road in breast cancer.
    Cancer Res. 2023 Dec 6. doi: 10.1158/0008-5472.CAN-23-3803.
    PubMed     Abstract available
    
    
    November 2023
17. KO JH, Lambert KE, Bhattacharya D, Lee MC, et al
    Small cell lung cancer plasticity enables NFIB-independent metastasis.
    Cancer Res. 2023 Nov 14. doi: 10.1158/0008-5472.CAN-23-1079.
    PubMed     Abstract available
    
    
    
18. PRAHALLAD A, Weiss A, Voshol H, Kerr G, et al
    CRISPR screening identifies mechanisms of resistance to KRASG12C and SHP2 inhibitor combinations in non-small cell lung cancer.
    Cancer Res. 2023 Nov 7. doi: 10.1158/0008-5472.CAN-23-1127.
    PubMed     Abstract available
    
    
    
19. WEBER MC, Izzo LT, Oliver TG
    Epigenetic Regulators Open the Door to SCLC Plasticity.
    Cancer Res. 2023;83:3495-3497.
    PubMed     Abstract available
    
    
    
20. COTTON JL, Estrada Diez J, Sagar V, Chen J, et al
    Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.
    Cancer Res. 2023;83:3611-3623.
    PubMed     Abstract available
    
    
    October 2023
21. HARIPRAKASH JM, Salviato E, La Mastra F, Sebestyen E, et al
    Leveraging tissue-specific enhancer-target gene regulatory networks identifies enhancer somatic mutations that functionally impact lung cancer.
    Cancer Res. 2023 Oct 19. doi: 10.1158/0008-5472.CAN-23-1129.
    PubMed     Abstract available
    
    
    
22. WU J, Subbiah V
    RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
    Cancer Res. 2023;83:3159-3161.
    PubMed     Abstract available
    
    
    
23. YANAGAWA J, Tran LM, Salehi-Rad R, Lim RJ, et al
    Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma.
    Cancer Res. 2023;83:3305-3319.
    PubMed     Abstract available
    
    
    
24. NAMBIAR DK, Viswanathan V, Cao H, Zhang W, et al
    Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment.
    Cancer Res. 2023;83:3205-3219.
    PubMed     Abstract available
    
    
    September 2023
25. KIM N, Hwang CY, Kim T, Kim H, et al
    A cell fate reprogramming strategy reverses epithelial-to-mesenchymal transition of lung cancer cells while avoiding hybrid states.
    Cancer Res. 2023 Sep 13:CAN-22-1559. doi: 10.1158/0008-5472.CAN-22-1559.
    PubMed     Abstract available
    
    
    August 2023
26. WALKER RR, Chiappinelli KB
    Protein Exaptation by Endogenous Retroviral Elements Shapes Tumor Cell Senescence and Downstream Immune Signaling.
    Cancer Res. 2023;83:2640-2642.
    PubMed     Abstract available
    
    
    
27. FAN F, Gao J, Zhao Y, Wang J, et al
    Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2+ Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma.
    Cancer Res. 2023;83:2690-2703.
    PubMed     Abstract available
    
    
    
28. MA S, Caligiuri MA, Yu J
    Harnessing Natural Killer Cells for Lung Cancer Therapy.
    Cancer Res. 2023 Aug 2:CAN-23-1097. doi: 10.1158/0008-5472.CAN-23-1097.
    PubMed     Abstract available
    
    
    
29. CUI W, Huang Z, Jin SG, Johnson J, et al
    Deficiency of the Polycomb Protein RYBP and TET Methylcytosine Oxidases Promotes Extensive CpG Island Hypermethylation and Malignant Transformation.
    Cancer Res. 2023;83:2480-2495.
    PubMed     Abstract available
    
    
    
30. MATHUR D, Liao C, Lin W, La Ferlita A, et al
    The ratio of key metabolic transcripts is a predictive biomarker of breast cancer metastasis to the lung.
    Cancer Res. 2023 Aug 1:CAN-23-0153. doi: 10.1158/0008-5472.CAN-23-0153.
    PubMed     Abstract available
    
    
    July 2023
31. ZHENG X, Sarode P, Weigert A, Turkowski K, et al
    The HDAC2-SP1 Axis Orchestrates Protumor Macrophage Polarization.
    Cancer Res. 2023;83:2345-2357.
    PubMed     Abstract available
    
    
    
32. YE F, Cai Z, Wang B, Zeng C, et al
    TGFbeta Antagonizes IFNgamma-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
    Cancer Res. 2023;83:2262-2277.
    PubMed     Abstract available
    
    
    
33. KA NL, Park MK, Kim SS, Jeon Y, et al
    NR1D1 stimulates antitumor immune responses in breast cancer by activating cGAS-STING signaling.
    Cancer Res. 2023 Jul 3:CAN-23-0329. doi: 10.1158/0008-5472.CAN-23-0329.
    PubMed     Abstract available
    
    
    June 2023
34. SCORTEGAGNA M, Du Y, Bradley LM, Wang K, et al
    Ubiquitin Ligases Siah1a/2 Control Alveolar Macrophage Functions to Limit Carcinogen-Induced Lung Adenocarcinoma.
    Cancer Res. 2023;83:2016-2033.
    PubMed     Abstract available
    
    
    
35. DEBLASI JM, Falzone A, Caldwell S, Prieto-Farigua N, et al
    Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression.
    Cancer Res. 2023;83:1953-1967.
    PubMed     Abstract available
    
    
    
36. EXPOSITO F, Redrado M, Houry M, Hastings K, et al
    PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells.
    Cancer Res. 2023 Jun 13:CAN-22-3023. doi: 10.1158/0008-5472.CAN-22-3023.
    PubMed     Abstract available
    
    
    
37. MULLER N, Lorenz C, Ostendorp J, Heisel FS, et al
    Characterizing evolutionary dynamics reveals strategies to exhaust the spectrum of subclonal resistance in EGFR-mutant lung cancer.
    Cancer Res. 2023 Jun 8:CAN-22-2605. doi: 10.1158/0008-5472.CAN-22-2605.
    PubMed     Abstract available
    
    
    May 2023
38. HU Q, Dai J, Zhang Z, Yu H, et al
    ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells.
    Cancer Res. 2023;83:1646-1665.
    PubMed     Abstract available
    
    
    
39. TOMOSHIGE K, Stuart WD, Fink-Baldauf IM, Ito M, et al
    FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung.
    Cancer Res. 2023;83:1443-1458.
    PubMed     Abstract available
    
    
    
40. ZHANG H, AbdulJabbar K, Moore DA, Akarca A, et al
    Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma.
    Cancer Res. 2023;83:1410-1425.
    PubMed     Abstract available
    
    
    April 2023
41. ZHANG H, Zhou J, Li J, Wang Z, et al
    N6-methyladenosine promotes translation of VEGFA to accelerate angiogenesis in lung cancer.
    Cancer Res. 2023 Apr 27:CAN-22-2449. doi: 10.1158/0008-5472.CAN-22-2449.
    PubMed     Abstract available
    
    
    
42. LIN Z, Li J, Zhang J, Feng W, et al
    Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer.
    Cancer Res. 2023 Apr 16:CAN-22-3059. doi: 10.1158/0008-5472.CAN-22-3059.
    PubMed     Abstract available
    
    
    
43. VRINZEN CEJ, Delfgou L, Stadhouders N, Hermens RPMG, et al
    A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer.
    Cancer Res. 2023;83:1147-1157.
    PubMed     Abstract available
    
    
    March 2023
44. HUANG X, Zhang S, Tang J, Tian T, et al
    A self-propagating c-Met-SOX2 axis drives cancer-derived IgG signaling that promotes lung cancer cell stemness.
    Cancer Res. 2023 Mar 29:CAN-22-2733. doi: 10.1158/0008-5472.CAN-22-2733.
    PubMed     Abstract available
    
    
    
45. JIN M, Liu B, Chen C, Huang Y, et al
    Genome-wide splicing QTL analysis identifies causal risk variants for non-small cell lung cancer.
    Cancer Res. 2023 Mar 20:CAN-22-3184. doi: 10.1158/0008-5472.CAN-22-3184.
    PubMed     Abstract available
    
    
    February 2023
46. BAO Y, Zhang S, Zhang X, Pan Y, et al
    RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition.
    Cancer Res. 2023 Feb 28:CAN-22-1549. doi: 10.1158/0008-5472.CAN-22-1549.
    PubMed     Abstract available
    
    
    
47. MANDELL JD, Cannataro VL, Townsend JP
    Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR.
    Cancer Res. 2023;83:500-505.
    PubMed     Abstract available
    
    
    
48. LUO Y, Liang H
    Cancer Cells Employ the Most Prolific RNA Editors: A Closer Look at the Single-Cell Level.
    Cancer Res. 2023;83:351-353.
    PubMed     Abstract available
    
    
    
49. CHAN TW, Dodson JP, Arbet J, Boutros PC, et al
    Single-Cell Analysis in Lung Adenocarcinoma Implicates RNA Editing in Cancer Innate Immunity and Patient Prognosis.
    Cancer Res. 2023;83:374-385.
    PubMed     Abstract available
    
    
    January 2023
50. CHENG LH, Hsu CC, Tsai HW, Liao WY, et al
    ASPM activates Hedgehog and Wnt signaling to promote small cell lung cancer stemness and progression.
    Cancer Res. 2023 Jan 13:CAN-22-2496. doi: 10.1158/0008-5472.CAN-22-2496.
    PubMed     Abstract available
    
    
    December 2022
51. WEIGEL C, Maczis MA, Palladino END, Green CD, et al
    Sphingosine kinase 2 in stromal fibroblasts creates a hospitable tumor microenvironment in breast cancer.
    Cancer Res. 2022 Dec 21:CAN-22-1638. doi: 10.1158/0008-5472.CAN-22-1638.
    PubMed     Abstract available
    
    
    
52. LONG LL, Ma SC, Guo ZQ, Zhang YP, et al
    PARP inhibition induces synthetic lethality and adaptive immunity in LKB1-mutant lung cancer.
    Cancer Res. 2022 Dec 13:CAN-22-1740. doi: 10.1158/0008-5472.CAN-22-1740.
    PubMed     Abstract available
    
    
    
53. GAN B
    A Time and Place for Inhibiting Autophagy.
    Cancer Res. 2022;82:4322-4324.
    PubMed     Abstract available
    
    
    November 2022
54. VAISHNAVI A, Juan J, Jacob M, Stehn C, et al
    Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.
    Cancer Res. 2022;82:4261-4273.
    PubMed     Abstract available
    
    
    
55. ZHU LY, Yuan JB, Zhang L, He CX, et al
    Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis.
    Cancer Res. 2022;82:4153-4163.
    PubMed     Abstract available
    
    
    
56. VAN GINDERACHTER JA
    The Heat Is On: 20-HETE Instructs an Immunosuppressive Phenotype in Cancer-Associated Fibroblasts.
    Cancer Res. 2022;82:3882-3883.
    PubMed     Abstract available
    
    
    
57. SCHARPF RB, Balan A, Ricciuti B, Fiksel J, et al
    Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.
    Cancer Res. 2022;82:4058-4078.
    PubMed     Abstract available
    
    
    
58. ROH W, Geffen Y, Cha H, Miller M, et al
    High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.
    Cancer Res. 2022;82:3917-3931.
    PubMed     Abstract available
    
    
    October 2022
59. LI M, Mok K, Mok T
    A Detouring Experience Not Recommended: Lessons Learned from PF00299804.
    Cancer Res. 2022;82:3662-3664.
    PubMed     Abstract available
    
    
    
60. ZHU Q, Zhang C, Qu T, Lu X, et al
    MNX1-AS1 promotes phase separation of IGF2BP1 to drive c-Myc-mediated cell cycle progression and proliferation in lung cancer.
    Cancer Res. 2022 Oct 10. pii: 709670. doi: 10.1158/0008-5472.CAN-22-1289.
    PubMed     Abstract available
    
    
    
61. LUO MY, Zhou Y, Gu WM, Wang C, et al
    Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma.
    Cancer Res. 2022;82:3516-3531.
    PubMed     Abstract available
    
    
    
62. DENG H, Lin C, Garcia-Gerique L, Fu S, et al
    A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression.
    Cancer Res. 2022;82:3561-3572.
    PubMed     Abstract available
    
    
    September 2022
63. KHAYATI K, Bhatt V, Lan T, Alogaili F, et al
    Transient Systemic Autophagy Inhibition is Selectively and Irreversibly Deleterious to Lung Cancer.
    Cancer Res. 2022 Sep 26. pii: 709374. doi: 10.1158/0008-5472.CAN-22-1039.
    PubMed     Abstract available
    
    
    
64. KIM KB, Kim DW, Kim Y, Tang J, et al
    WNT5A-RHOA signaling is a driver of tumorigenesis and represents a therapeutically actionable vulnerability in small cell lung cancer.
    Cancer Res. 2022 Sep 14. pii: 709197. doi: 10.1158/0008-5472.CAN-22-1170.
    PubMed     Abstract available
    
    
    
65. WOO XY, Srivastava A, Mack PC, Graber JH, et al
    A Genomically and Clinically Annotated Patient-Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer.
    Cancer Res. 2022 Sep 7. pii: 709108. doi: 10.1158/0008-5472.CAN-22-0948.
    PubMed     Abstract available
    
    
    
66. YOSHIDA R, Saigi M, Tani T, Springer BF, et al
    MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer.
    Cancer Res. 2022 Sep 6. pii: 708983. doi: 10.1158/0008-5472.CAN-22-0770.
    PubMed     Abstract available
    
    
    
67. TREFZER TB, Schneider MA, Jechow K, Chua RL, et al
    Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers.
    Cancer Res. 2022;82:3116-3129.
    PubMed     Abstract available
    
    
    August 2022
68. CHOI YJ, Kim DS, Sung YH, Kim DH, et al
    Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
    Cancer Res. 2022 Aug 26:OF1. doi: 10.1158/0008-5472.CAN-22-2507.
    PubMed    
    
    
    
69. CHOI YJ, Kim DS, Sung YH, Kim DH, et al
    Correction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
    Cancer Res. 2022 Aug 25:OF1. doi: 10.1158/0008-5472.CAN-22-2377.
    PubMed    
    
    
    
70. CHEN X, Liu Y, Wang Y, Wang C, et al
    CYP4F2-catalyzed metabolism of arachidonic acid promotes stromal cell-mediated immunosuppression in non-small cell lung cancer.
    Cancer Res. 2022 Aug 24. pii: 708709. doi: 10.1158/0008-5472.CAN-21-4029.
    PubMed     Abstract available
    
    
    
71. ROLFO C, Malapelle U, Russo A
    Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients.
    Cancer Res. 2022;82:2826-2828.
    PubMed     Abstract available
    
    
    
72. CHRISTENSEN DS, Ahrenfeldt J, Sokac M, Kisistok J, et al
    Treatment Represents a Key Driver of Metastatic Cancer Evolution.
    Cancer Res. 2022;82:2918-2927.
    PubMed     Abstract available
    
    
    
73. HONG CL, Yu IS, Pai CH, Chen JS, et al
    CD248 regulates Wnt signaling in pericytes to promote angiogenesis and tumor growth in lung cancer.
    Cancer Res. 2022 Aug 11. pii: 707659. doi: 10.1158/0008-5472.CAN-22-1695.
    PubMed     Abstract available
    
    
    
74. BOUMELHA J, de Carne Trecesson S, Law EK, Romero-Clavijo P, et al
    An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations.
    Cancer Res. 2022 Aug 5. pii: 707449. doi: 10.1158/0008-5472.CAN-22-0325.
    PubMed     Abstract available
    
    
    
75. THEGE FI, Rupani DN, Barathi BB, Manning SL, et al
    A Programmable In Vivo CRISPR Activation Model Elucidates the Oncogenic and Immunosuppressive Functions of MYC in Lung Adenocarcinoma.
    Cancer Res. 2022;82:2761-2776.
    PubMed     Abstract available
    
    
    July 2022
76. LEE J, Bayik D, Lathia JD
    Preinvasive to Invasive: PD-1-Expressing Macrophages Shift Lung Cancer into High Gear.
    Cancer Res. 2022;82:2515-2516.
    PubMed     Abstract available
    
    
    
77. JANG HJ, Lee HS, Yu W, Ramineni M, et al
    Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.
    Cancer Res. 2022;82:2593-2609.
    PubMed     Abstract available
    
    
    June 2022
78. KELENIS DP, Rodarte KE, Kollipara RK, Pozo K, et al
    Inhibition of karyopherin beta1-mediated nuclear import disrupts oncogenic lineage- defining transcription factor activity in small cell lung cancer.
    Cancer Res. 2022 Jun 24. pii: 705062. doi: 10.1158/0008-5472.CAN-21-3713.
    PubMed     Abstract available
    
    
    
79. NAIR VS, Hui AB, Chabon JJ, Shahrokh Esfahani M, et al
    Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.
    Cancer Res. 2022 Jun 24. pii: 705060. doi: 10.1158/0008-5472.CAN-22-0554.
    PubMed     Abstract available
    
    
    
80. KARLOW JA, Devarakonda S, Xing X, Jang HS, et al
    Developmental pathways are epigenetically reprogrammed during lung cancer brain metastasis.
    Cancer Res. 2022 Jun 15. pii: 704908. doi: 10.1158/0008-5472.CAN-21-4160.
    PubMed     Abstract available
    
    
    
81. CHOI YJ, Kim DS, Hoon Sung Y, Kim DH, et al
    The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
    Cancer Res. 2022 Jun 14. pii: 704898. doi: 10.1158/0008-5472.CAN-22-0394.
    PubMed     Abstract available
    
    
    April 2022
82. YOUSEFI M, Boross G, Weiss C, Murray CW, et al
    Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.
    Cancer Res. 2022;82:1589-1602.
    PubMed     Abstract available
    
    
    
83. PAL AS, Agredo A, Lanman NA, Son J, et al
    Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET.
    Cancer Res. 2022;82:1534-1547.
    PubMed     Abstract available
    
    
    
84. WANG F, Liu Y, Qiu W, Shum E, et al
    Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination.
    Cancer Res. 2022;82:1365-1379.
    PubMed     Abstract available
    
    
    
85. HONG Z, Liu T, Wan L, Fa P, et al
    Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy.
    Cancer Res. 2022;82:1298-1312.
    PubMed     Abstract available
    
    
    March 2022
86. OSBORNE JK, Minna JD
    Lung Cancer Cell of Origin: Controversy and Clinical Translational Implications.
    Cancer Res. 2022;82:972-973.
    PubMed     Abstract available
    
    
    February 2022
87. SON J, Jang J, Beyett TS, Eum Y, et al
    A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer.
    Cancer Res. 2022 Feb 11. pii: 0008-5472.CAN-21-2693.
    PubMed     Abstract available
    
    
    January 2022
88. YIN H, Jing B, Xu D, Guo W, et al
    Identification of Active Bronchioalveolar Stem Cells as the Cell-of-Origin in Lung Adenocarcinoma.
    Cancer Res. 2022 Jan 19. pii: 0008-5472.CAN-21-2445.
    PubMed     Abstract available
    
    
    
89. HAJ-SHOMALY J, Vorontsova A, Barenholz-Cohen T, Levi-Galibov O, et al
    T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy.
    Cancer Res. 2022;82:278-291.
    PubMed     Abstract available
    
    
    
90. LIU X, Li Z, Wang Z, Liu F, et al
    Chromatin remodeling induced by ARID1A loss in lung cancer promotes glycolysis and confers JQ1 vulnerability.
    Cancer Res. 2022 Jan 5. pii: 0008-5472.CAN-21-0763.
    PubMed     Abstract available
    
    
    
91. LIM SM, Kim CG, Cho BC
    Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer.
    Cancer Res. 2022;82:18-20.
    PubMed     Abstract available
    
    
    
92. ISHOLA AA, Chien CS, Yang YP, Chien Y, et al
    Oncogenic circRNA C190 Promotes Non-Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway.
    Cancer Res. 2022;82:75-89.
    PubMed     Abstract available
    
    
    December 2021
93. OBA T, Kajihara R, Yokoi T, Repasky EA, et al
    Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors.
    Cancer Res. 2021;81:6183-6195.
    PubMed     Abstract available
    
    
    
94. CHEN X, Zhao Y, Wang D, Lin Y, et al
    The HNF4alpha-BC200-FMR1-Positive Feedback Loop Promotes Growth and Metastasis in Invasive Mucinous Lung Adenocarcinoma.
    Cancer Res. 2021;81:5904-5918.
    PubMed     Abstract available
    
    
    November 2021
95. HONG W, Li A, Liu Y, Xiao X, et al
    Clonal Hematopoiesis Mutations in Lung Cancer Patients are Associated with Lung Cancer Risk Factors.
    Cancer Res. 2021 Nov 23. pii: 0008-5472.CAN-21-1903.
    PubMed     Abstract available
    
    
    
96. QUINTANAL-VILLALONGA A, Taniguchi H, Hao Y, Chow A, et al
    Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy.
    Cancer Res. 2021 Nov 23. pii: 0008-5472.CAN-21-2964.
    PubMed     Abstract available
    
    
    
97. HONG D, Knelson EH, Li Y, Durmaz YT, et al
    Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-1991.
    PubMed     Abstract available
    
    
    
98. SUBRAMANIAN S, Daquinag AC, AghaAmiri S, Ghosh SC, et al
    Characterization of Peptides Targeting Metastatic Tumor Cells as Probes for Cancer Detection and Vehicles for Therapy Delivery.
    Cancer Res. 2021;81:5756-5764.
    PubMed     Abstract available
    
    
    
99. JANJANAM J, Pano G, Wang R, Minden-Birkenmaier BA, et al
    Matricellular Protein WISP2 Is an Endogenous Inhibitor of Collagen Linearization and Cancer Metastasis.
    Cancer Res. 2021;81:5666-5677.
    PubMed     Abstract available
    
    
    
100. WU B, Ye Y, Xie S, Li Y, et al
     Megakaryocytes Mediate Hyperglycemia-Induced Tumor Metastasis.
     Cancer Res. 2021;81:5506-5522.
     PubMed     Abstract available
     
     
     
101. GRISARU-TAL S, Dulberg S, Beck L, Zhang C, et al
     Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity.
     Cancer Res. 2021;81:5555-5571.
     PubMed     Abstract available
     
     
     October 2021
102. DONE SJ, Kanwar N, Balde Z, Nair R, et al
     Heterogeneity of circulating tumor cell-associated genomic gains in breast cancer and its association with the host immune response.
     Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1079.
     PubMed     Abstract available
     
     
     
103. KUNZKE T, Prade VM, Buck A, Sun N, et al
     Patterns of carbon-bound exogenous compounds in lung cancer patients and association with disease pathophysiology.
     Cancer Res. 2021 Oct 19. pii: 0008-5472.CAN-21-1175.
     PubMed     Abstract available
     
     
     
104. HUGGINS DN, LaRue RS, Wang Y, Knutson TP, et al
     Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset.
     Cancer Res. 2021;81:5284-5295.
     PubMed     Abstract available
     
     
     
105. HAN H, Li S, Chen T, Fitzgerald M, et al
     Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.
     Cancer Res. 2021;81:5311-5324.
     PubMed     Abstract available
     
     
     September 2021
106. ZHAO Z, Szczepanski AP, Tsuboyama N, Abdala-Valencia H, et al
     PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer.
     Cancer Res. 2021;81:4696-4708.
     PubMed     Abstract available
     
     
     
107. SATO R, Imamura K, Semba T, Tomita Y, et al
     TGFbeta Signaling Activated by Cancer-Associated Fibroblasts Determines the Histological Signature of Lung Adenocarcinoma.
     Cancer Res. 2021;81:4751-4765.
     PubMed     Abstract available
     
     
     
108. KODAMA M, Shimura H, Tien JC, Newberg JY, et al
     Sleeping Beauty transposon mutagenesis identifies genes driving the initiation and metastasis of uterine leiomyosarcoma.
     Cancer Res. 2021 Sep 2. pii: 0008-5472.CAN-21-0356.
     PubMed     Abstract available
     
     
     
109. LI C, Lin WY, Rizvi H, Cai H, et al
     Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma.
     Cancer Res. 2021;81:4570-4580.
     PubMed     Abstract available
     
     
     August 2021
110. YU TJ, Liu YY, Li XG, Lian B, et al
     PDSS1-mediated activation of CAMK2A-STAT3 signaling promotes metastasis in triple-negative breast cancer.
     Cancer Res. 2021 Aug 18. pii: 0008-5472.CAN-21-0747.
     PubMed     Abstract available
     
     
     
111. KOENIG MJ, Agana BA, Kaufman JM, Sharpnack MF, et al
     STK11/LKB1 Loss of Function Is Associated with Global DNA Hypomethylation and S-Adenosyl-Methionine Depletion in Human Lung Adenocarcinoma.
     Cancer Res. 2021;81:4194-4204.
     PubMed     Abstract available
     
     
     
112. WANG X, Chen Y, Wang X, Tian H, et al
     Stem cell factor SOX2 confers ferroptosis resistance in lung cancer via upregulation of SLC7A11.
     Cancer Res. 2021 Aug 12. pii: 0008-5472.CAN-21-0567.
     PubMed     Abstract available
     
     
     July 2021
113. KASHIMA Y, Shibahara D, Suzuki A, Muto K, et al
     Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer.
     Cancer Res. 2021 Jul 9. pii: 0008-5472.CAN-20-2811.
     PubMed     Abstract available
     
     
     
114. VON ITZSTEIN MS, Gerber DE, Minna JD
     Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers.
     Cancer Res. 2021;81:3441-3443.
     PubMed     Abstract available
     
     
     June 2021
115. LI HJ, Ke FY, Lin CC, Lu MY, et al
     ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-mesenchymal transition.
     Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-3543.
     PubMed     Abstract available
     
     
     
116. SHARIF GM, Campbell MJ, Nasir A, Sengupta S, et al
     An AIB1 isoform alters enhancer access and enables progression of early stage triple-negative breast cancer.
     Cancer Res. 2021 Jun 16. pii: 0008-5472.CAN-20-3625.
     PubMed     Abstract available
     
     
     
117. CHANG A, Liu L, Ashby JM, Wu D, et al
     Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
     Cancer Res. 2021;81:3358-3373.
     PubMed     Abstract available
     
     
     
118. TU HF, Ko CJ, Lee CT, Lee CF, et al
     Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD.
     Cancer Res. 2021;81:3270-3282.
     PubMed     Abstract available
     
     
     
119. DE LOGU F, Marini M, Landini L, Souza Monteiro de Araujo D, et al
     Peripheral Nerve Resident Macrophages and Schwann Cells Mediate Cancer-Induced Pain.
     Cancer Res. 2021;81:3387-3401.
     PubMed     Abstract available
     
     
     
120. ISHIOKA K, Yasuda H, Hamamoto J, Terai H, et al
     Upregulation of fibroblast growth factor 9 in lung adenocarcinoma transdifferentiation to small cell lung cancer.
     Cancer Res. 2021 Jun 3. pii: 0008-5472.CAN-20-4048.
     PubMed     Abstract available
     
     
     
121. CHABANON RM, Morel D, Eychenne T, Colmet-Daage L, et al
     PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
     Cancer Res. 2021;81:2888-2902.
     PubMed     Abstract available
     
     
     
122. ZHANG X, Maity TK, Ross KE, Qi Y, et al
     Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
     Cancer Res. 2021;81:3051-3066.
     PubMed     Abstract available
     
     
     
123. KUREBAYASHI Y, Olkowski CP, Lane KC, Vasalatiy OV, et al
     Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNgamma-Dependent Tumor Vessel Regression.
     Cancer Res. 2021;81:3092-3104.
     PubMed     Abstract available
     
     
     May 2021
124. DENEKA AY, Kopp MC, Nikonova AS, Gaponova AV, et al
     Nedd9 restrains autophagy to limit growth of early stage non-small cell lung cancer.
     Cancer Res. 2021 May 18. pii: 0008-5472.CAN-20-3626.
     PubMed     Abstract available
     
     
     
125. WANG C, Meng X, Zhou Y, Yu J, et al
     Long noncoding RNA CTD-2245E15.3 promotes anabolic enzymes ACC1 and PC to support non-small cell lung cancer growth.
     Cancer Res. 2021 May 3. pii: 0008-5472.CAN-19-3806.
     PubMed     Abstract available
     
     
     
126. REN J, He J, Zhang H, Xia Y, et al
     Platelet TLR4-ERK5 Axis Facilitates NET-Mediated Capturing of Circulating Tumor Cells and Distant Metastasis after Surgical Stress.
     Cancer Res. 2021;81:2373-2385.
     PubMed     Abstract available
     
     
     April 2021
127. FUHRMAN BJ, Moore SC, Byrne C, Makhoul I, et al
     Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts.
     Cancer Res. 2021;81:2246-2255.
     PubMed     Abstract available
     
     
     
128. KOVALENKO A, Sanin A, Kosmas K, Zhang L, et al
     Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.
     Cancer Res. 2021;81:2086-2100.
     PubMed     Abstract available
     
     
     
129. MUSOLF AM, Simpson CL, Moiz BA, Pikielny CW, et al
     Genetic variation and recurrent haplotypes on chromosome 6q23-25 risk locus in familial lung cancer.
     Cancer Res. 2021 Apr 14. pii: 0008-5472.CAN-20-3196.
     PubMed     Abstract available
     
     
     
130. LI R, Salehi-Rad R, Crosson W, Momcilovic M, et al
     Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-deficient Non-Small Cell Lung Cancer.
     Cancer Res. 2021 Apr 14. pii: 0008-5472.CAN-20-3564.
     PubMed     Abstract available
     
     
     
131. LIN EP, Huang BT, Lai WY, Tseng YT, et al
     PINK1-Mediated Inhibition of EGFR Dimerization and Activation Impedes EGFR-Driven Lung Tumorigenesis.
     Cancer Res. 2021;81:1745-1757.
     PubMed     Abstract available
     
     
     
132. CHEN F, Chen Z, Guan T, Zhou Y, et al
     N6-methyladenosine regulates mRNA stability and translation efficiency of KRT7 to promote breast cancer lung metastasis.
     Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-3779.
     PubMed     Abstract available
     
     
     March 2021
133. KONEN JM, Rodriguez BL, Padhye A, Ochieng JK, et al
     Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
     Cancer Res. 2021;81:1398-1412.
     PubMed     Abstract available
     
     
     
134. DAI M, Boudreault J, Wang N, Poulet S, et al
     Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
     Cancer Res. 2021;81:1332-1346.
     PubMed     Abstract available
     
     
     February 2021
135. YU R, Longo J, van Leeuwen JE, Zhang C, et al
     Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching.
     Cancer Res. 2021 Feb 18. pii: 0008-5472.CAN-20-2642.
     PubMed     Abstract available
     
     
     
136. SIN TK, Zhang G, Zhang Z, Zhu JZ, et al
     Cancer-Induced Muscle Wasting Requires p38beta MAPK Activation of p300.
     Cancer Res. 2021;81:885-897.
     PubMed     Abstract available
     
     
     
137. ZHOU J, Li Q, Cao Y
     Spatiotemporal Heterogeneity Across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer.
     Cancer Res. 2021 Feb 15. pii: 0008-5472.CAN-20-3665.
     PubMed     Abstract available
     
     
     
138. SINGH S, Sutcliffe MD, Repich K, Atkins KA, et al
     Pan-cancer Drivers are Recurrent Transcriptional Regulatory Heterogeneities in Early-stage Luminal Breast Cancer.
     Cancer Res. 2021 Feb 2. pii: 0008-5472.CAN-20-1034.
     PubMed     Abstract available
     
     
     
139. HILFENHAUS G, Mompeon A, Freshman J, Prajapati DP, et al
     A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier.
     Cancer Res. 2021;81:619-633.
     PubMed     Abstract available
     
     
     
140. CRESSWELL GM, Wang B, Kischuk EM, Broman MM, et al
     Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
     Cancer Res. 2021;81:671-684.
     PubMed     Abstract available
     
     
     
141. ROSSI G, Barabino E, Fedeli A, Ficarra G, et al
     Radiomic Detection of EGFR Mutations in NSCLC.
     Cancer Res. 2021;81:724-731.
     PubMed     Abstract available
     
     
     January 2021
142. KOLAPALLI SP, Sahu R, Chauhan NR, Jena KK, et al
     RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression.
     Cancer Res. 2021;81:315-331.
     PubMed     Abstract available
     
     
     
143. XING F, Zhao D, Wu SY, Tyagi A, et al
     Epigenetic and post-transcriptional modulation of SOS1 can promote breast cancer metastasis through obesity-activated c-Met signaling in African American women.
     Cancer Res. 2021 Jan 14. pii: 0008-5472.CAN-19-4031.
     PubMed     Abstract available
     
     
     
144. KAMIYAMA M, Augustin HG
     Alternatively Spliced Form of Angiopoietin-2 as a New Vascular Rheostat.
     Cancer Res. 2021;81:35-37.
     PubMed     Abstract available
     
     
     
145. KAPIAINEN E, Kihlstrom MK, Pietila R, Kaakinen M, et al
     The Amino-Terminal Oligomerization Domain of Angiopoietin-2 Affects Vascular Remodeling, Mammary Gland Tumor Growth, and Lung Metastasis in Mice.
     Cancer Res. 2021;81:129-143.
     PubMed     Abstract available
     
     
     
146. JEONG GY, Park MK, Choi HJ, An HW, et al
     NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression.
     Cancer Res. 2021;81:77-90.
     PubMed     Abstract available
     
     
     December 2020
147. DOUGLASS SM, Fane ME, Sanseviero E, Ecker BL, et al
     Myeloid-derived suppressor cells are a major source of Wnt5A in the melanoma microenvironment and depend on Wnt5A for full suppressive activity.
     Cancer Res. 2020 Dec 1. pii: 0008-5472.CAN-20-1238.
     PubMed     Abstract available
     
     
     October 2020
148. WILLS CA, Liu X, Chen L, Zhao Y, et al
     Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis.
     Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1976.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.